Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its position in shares of Penumbra, Inc. (NYSE:PEN – Get Rating) by 2.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,649 shares of the company’s stock after acquiring an additional 571 shares during the quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. owned 0.05% of Penumbra worth $3,915,000 as of its most recent SEC filing.
Other large investors have also made changes to their positions in the company. Captrust Financial Advisors raised its holdings in shares of Penumbra by 44.1% during the second quarter. Captrust Financial Advisors now owns 219 shares of the company’s stock valued at $27,000 after acquiring an additional 67 shares during the period. WASHINGTON TRUST Co purchased a new position in Penumbra during the second quarter valued at approximately $31,000. Wipfli Financial Advisors LLC purchased a new position in Penumbra during the third quarter valued at approximately $40,000. Quantbot Technologies LP purchased a new position in Penumbra during the second quarter valued at approximately $94,000. Finally, Covestor Ltd grew its position in Penumbra by 190.8% during the first quarter. Covestor Ltd now owns 442 shares of the company’s stock valued at $98,000 after purchasing an additional 290 shares in the last quarter. Institutional investors and hedge funds own 82.42% of the company’s stock.
Analysts Set New Price Targets
A number of research analysts recently commented on the stock. Needham & Company LLC lowered their price objective on shares of Penumbra from $244.00 to $235.00 and set a “buy” rating on the stock in a research report on Friday, November 4th. BTIG Research boosted their price objective on shares of Penumbra from $204.00 to $240.00 and gave the company a “buy” rating in a research report on Monday, December 5th. Wells Fargo & Company boosted their price objective on shares of Penumbra from $225.00 to $255.00 and gave the company an “overweight” rating in a research report on Monday, December 12th. Citigroup boosted their price objective on shares of Penumbra from $212.00 to $270.00 and gave the company a “buy” rating in a research report on Monday, December 12th. Finally, Canaccord Genuity Group decreased their target price on shares of Penumbra from $203.00 to $185.00 and set a “buy” rating for the company in a research report on Friday, November 4th. One investment analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $238.55.
Insider Transactions at Penumbra
Penumbra Price Performance
Shares of Penumbra stock opened at $239.66 on Friday. The firm has a fifty day simple moving average of $216.08 and a 200-day simple moving average of $183.27. The company has a current ratio of 5.23, a quick ratio of 2.92 and a debt-to-equity ratio of 0.03. Penumbra, Inc. has a 1-year low of $114.86 and a 1-year high of $246.01. The stock has a market capitalization of $9.10 billion, a price-to-earnings ratio of -292.26 and a beta of 0.48.
Penumbra (NYSE:PEN – Get Rating) last issued its quarterly earnings data on Thursday, November 3rd. The company reported $0.01 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.02. Penumbra had a negative net margin of 3.68% and a positive return on equity of 0.45%. The business had revenue of $213.68 million during the quarter, compared to analysts’ expectations of $212.41 million. On average, sell-side analysts expect that Penumbra, Inc. will post 0.14 earnings per share for the current year.
Penumbra Company Profile
Penumbra, Inc engages in the design, development, manufacture, and marketing of innovative medical devices. It offers neurovascular thrombectomy and embolization and access technologies, neurosurgical tools, Penumbra LANTERN Delivery Microcatheter, and Penumbra Occlusion Device (POD) system. Its target markets include interventional neuroradiologists, neurosurgeons, neurologists, cardiologists, radiologists, and vascular surgeons.
- Get a free copy of the StockNews.com research report on Penumbra (PEN)
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
- Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
- Does a Price Cut for Tesla Vehicles Mean the Same for TSLA Stock?
- Microsoft Layoffs Signal Layoffs for Other Tech Companies?
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.